Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Journal of Immunotherapy and Precision Oncology|August 29, 2022
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University ExperienceDylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist|February 26, 2021
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint InhibitorsJacqueline T Brown, Yuan Liu, Julie M Shabto, et al.
Frontiers in Oncology|July 5, 2021
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint BlockadeT Anders Olsen, Dylan J Martini, Subir Goyal, et al.
Frontiers in Oncology|July 26, 2021
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint InhibitorsDylan J Martini, T Anders Olsen, Subir Goyal, et al.
The Oncologist|June 7, 2023
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint InhibitorsGregory E Sanda, Julie M Shabto, Subir Goyal, et al.
Clinical Genitourinary Cancer|December 19, 2021
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma PatientsDylan J Martini, Sean T Evans, Yuan Liu, et al.
Cancer|November 16, 2021
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920Hamid Emamekhoo, Mark R Olsen, Bradley C Carthon, et al.
The Oncologist|June 22, 2021
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsDylan J Martini, Subir Goyal, Yuan Liu, et al.
Lancet (London, England)|May 10, 2021
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trialAshesh B Jani, Eduard Schreibmann, Subir Goyal, et al.
Cancer|February 11, 2026
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panelRana R McKay, Benjamin L Maughan, Alicia K Morgans, et al.
Pageof 6